RA Capital Healthcare Fund LP 4

What Happened

• RA Capital Management, L.P. (reported as a 10% owner and investment manager for the RA Capital Healthcare Fund) sold a total of 849,257 common shares of Vor Biopharma (VOR) in multiple open‑market/private sale transactions. The sales generated aggregate proceeds of approximately $14,518,964.
• Reported trades by date and line items: 258,475 shares at a weighted $18.23 ($4.71M) and 1,525 at $19.06 ($29.1K) on Apr 2, 2026; and 537,754 at $16.51 ($8.88M), 44,728 at $17.31 ($774.2K), and 6,775 at $18.50 (~$125.3K) on Apr 6, 2026. These are sales (code S), not purchases.

Key Details

• Transaction dates: Apr 2, 2026 and Apr 6, 2026; filed on Apr 6, 2026 (filing appears timely under the two-business‑day rule).
• Total shares sold: 849,257; total proceeds: ~$14.52M.
• Prices reported are weighted averages; the filing includes footnotes showing the underlying trade price ranges (examples: $18.05–$19.04, $19.05–$19.09, $16.25–$17.245, $17.25–$18.20).
• Ownership/structure notes: RA Capital Management is the adviser to the RA Capital Healthcare Fund (the shares were held directly by the Fund). The Adviser, its GP and individual named members disclaim beneficial ownership except for pecuniary interests, per the filing.
• Board connection: Dr. Andrew Levin, a Partner and Managing Director of the Adviser, serves on Vor Biopharma’s board of directors (disclosed in remarks).
• Shares owned after the transactions are not specified in the excerpt provided.

Context

• These are institutional sales by a 10% reporting owner (RA Capital/its Fund), not a simple insider purchase that might be read as a bullish signal. Sales by institutions can reflect portfolio rebalancing or other fund-level reasons; the filing gives no explanation of motive.
• The filing’s footnotes clarify that reported prices are weighted averages across multiple trades and that the Adviser manages the Fund that directly held the sold shares.